Taxanes act as vascular disrupting agents and increase rate of metastasis when combined with anti-angiogenic therapy
Nandigama, R.; Kallius, M.; Hemmen, K.; Shaoli, D.; Pinnecker, J.; Ascheid, D.; Burkhard, V.; Ali, H.; Scheld, D.; Herterich, S.; Zernecke, A.; Penack, O.; Diller, S.; Camphausen, K.; Erguen, S.; Shankavaram, U.; Heinze, K.; Escorcia, F.; Henke, E.
Show abstract
Taxanes are known to have a profound effect on endothelial cells and the vasculature even at low doses. Here, we show that taxanes, rather than being anti-angiogenic, function more as vascular disrupting agents (VDAs), although they exert a different mechanism of vascular permeabilization when compared to traditional VDAs such as combretastatins. In the tumor context, this VDA-effect leads to a rapid vascular collapse and acute hypoxia. Concomitant treatment with anti-VEGF drugs aggravates hypoxia by blocking vasculogenic rescue mechanisms. While this results in a strong growth-suppressing effect on the tumor, it also increases its invasiveness and metastatic potential. We demonstrate that combination of anti-angiogenic drugs with taxanes blocks tumor reperfusion, intensifies intravasation of circulating tumor cells (CTCs) and strongly increases metastasis. Anti-VEGF drugs are commonly applied in combination with cytotoxic drugs including taxanes. Our findings have significant implications for the clinical use of this drug combination.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- HIF-dependent expression of creatine kinase brain isoform (CKB) promotes breast cancer metastasis, whereas cyclocreatine therapy impairs invasion and improves the efficacy of conventional chemotherapies 96%
- HERC1 regulates breast cancer cells migration and invasion 96%
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
Similar papers in this journal
- Platinum chemotherapy induces lymphangiogenesis in cancerous and healthy tissues that can be prevented with adjuvant anti-VEGFR3 therapy 96%
- A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors 95%
- A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas 95%
Similar papers in this journal
- Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response 95%
- FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer. 95%
- Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodeling 94%
Similar papers in this journal
- Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer 96%
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase 95%
- Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets 94%
Similar papers in this journal
- Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 95%
- EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition 95%
- The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.